Recent Company News

• 03:14 AM ET Aug 03, 2026
  

  Nippon Kayaku Co. reports Q1 net income attributable ¥6.08B, +42% vs year-ago ¥4.29B (¥1951.5000, 0)

• 05:28 AM ET Jun 18, 2026
  

  Celltrion notes part 1 approval for European Phase 3 Clinical Trial Plan for CT-P13 SC has expired (KRW 173600.0000, 0)

• 11:01 PM ET May 25, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (110 total)

• 04:43 AM ET May 25, 2026
  

  Nippon Kayaku Co. reaches succession of marketing approval deal with AstraZeneca for Zoladex in Japan (¥2145.5000, 0)

• 12:21 AM ET May 25, 2026
  

  Nippon Kayaku Co. enters agreement to take over Japan marketing authorization for AstraZeneca's Zoladex 3.6mg/10.8mg depot (¥2140.5000, +50)

• 11:10 PM ET May 12, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (93 total)

• 11:02 PM ET May 12, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 03:12 AM ET May 12, 2026
  

  Nippon Kayaku Co. launches ¥15.0B buyback to repurchase up to 13.0M shares; to run from tomorrow through 31-Mar-2027 (¥1780.5000, 0)

• 03:09 AM ET May 12, 2026
  

  Nippon Kayaku Co. reports FY net income attributable ¥24.64B vs guidance ¥20.40B and FactSet ¥21.10B [2 est, ¥20.60-21.60B] (¥1780.5000, 0)

• 09:58 PM ET Apr 05, 2026
  

  Nippon Kayaku Co. completes up to 14M-share buyback (¥1783.5000, +10)